Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: A systematic review and meta-analysis
JAMA Oncology | Mar 03, 2018
Ritchie G, et al. - This study was implemented to determine the types of primary end points used in phase 2 checkpoint-inhibitor trials. Furthermore, researchers evaluated the strength of associations for objective response rate (ORR) with progression-free survival (PFS) and overall survival (OS). Findings demonstrated poor correlation of ORR with OS in checkpoint-inhibitor trials. Six-month PFS rate was recommended as an end point for future phase 2 studies.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
